No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

1

2/2

Genentech
(Roche)

SanegeneBio

n/d

RNAi platform

n/d

n/d

n/d

1,700+

2

2/5

Eisai

Shanghai Henlius
 Biotech

Serplulimab

αPD-1 mAb

Oncology

sqNSCLC, nsNSCLC, ESCC

ES-SCLC

Marketed

Phase 3

388

3

2/5

Everest

Medicines

Shaanxi Micot
 Pharmaceutical
 Technology

MT1013

Dual-targeting receptor

agonist polypeptide

(Calcium-sensing receptor,

Osteogenic growth peptide

receptor)

Renal disease

Chronic kidney diseases(CKD);

Secondary hyperparathyroidism

Phase 3

179

4

2/8

Eli Lilly

Innovent Biologics

n/d

n/d

Oncology

Immunology

n/d

n/d

8,850+

5

2/9

Takeda

Iambic

Therapeutics

‘NeuralPLexer’ Platform

AI-driven model for predicting

protein-ligand complexes

Oncology

Gastrointestinal

Inflammation

n/d

n/d

1,700+

6

2/9

CSL

Memo

Therapeutics

‘DROPZYLLA’ Platform

Recombinant polyclonal IgG

technology

n/d

n/d

n/d

328

7

2/11

Madrigal

Pharmaceuticals

Suzhou Ribo
Life Science

‘GalSTAR ™’
Platform

6 siRNA programs (including

bi-specific siRNAs)

Metabolic disorder

MASH

Preclinical

4,460+

8

2/16

Gilead Sciences

Genhouse Bio

GH31

MAT2A-targetting synthetic

lethal therapy

Oncology

Solid tumors

IND

1,530

9

2/17

Daiichi Sankyo

BostonGene

Multimodal AI
Platform

AI Foundation Models to

Enable Precision ADC

Clinical Development and

Response Intelligence

Oncology

n/d

n/d

n/d

10

2/18

Novartis

Unnatural Products

n/d

AI-driven model for the

selective design of

macrocycles

Cardiovascular disease

n/d

Preclinical

1,700+

11

2/18

Eli Lilly

CSL

Clazakizumab

αIL-6 mAb

Renal disease

End-stage kidney disease(ESKD)

Phase 3

100+

12

2/22

Solstice

Oncology

Harbour BioMed

Porustobart

(HBM4003)

αCTLA-4 mAb

Oncology

Solid tumors; Liver cancer,

Melanoma, Renal cancer, …

Phase 1/2

1,205+

13

2/23

Astellas

Vir Biotechnology

VIR-5500

PSMAxCD3 BsAbs

Oncology

Prostate cancer

Phase 1

1,705

14

2/24

LigaChem

Biosciences

NovaRock

Biotherapeutics

n/d

ADC

Oncology

n/d

n/d

n/d

15

2/24

GSK

Frontier

Biotechnologies

n/d

n/d

siRNA

siRNA

n/d

n/d

n/d

n/d

IND

Phase 1

1,003

16

2/24

Pfizer

Sciwind Biosciences

Ecnoglutide

cAMP-biased GLP-1 analogue

Metabolic disorder

Diabetes

Approved

495

17

2/25

Novo Nordisk

Vivtex corporation

-

Selective oral drug delivery

platforms

Metabolic disorder

Obesity, Diabetes

-

2,100

18

2/26

Boehringer

Ingelheim

Sitryx Therapeutics

n/d

Oral immunometabolic

modulator

Immunology

Multiple autoimmune and

inflammatory disease

Preclinical

500+

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

1

2/9

Eli Lilly

Orna Therapeutics

ORN-262

CD19 CAR-T

Immunology

B cell-driven autoimmune diseases

IND

2,400

2

2/18

Sensei

Biotherapeutics

Faeth Therapeutics

PIKTOR

(Serabelisib +

Sapanisertib)

PI3K/AKT/mTOR pathway inhibitors

Oncology

Advanced endometrial
 cancer

HR+/HER2- advanced
 breast cancer

Phase 2

Phase 1b

200

3

2/24

Gilead Sciences

Arcellx

Anitocabtagene

autoleucel

BCMA CAR-T

Oncology

Multiple myeloma

Phase 3

7,800

4

2/25

GSK

35Pharma

HS235

Activin signalling inhibitor

Cardiovascular disease

Hypertension

Phase 1

950